

LETTER FROM THE PRESIDENT & CEO OF METISCAN, INC.

December 5th, 2011

Dear Shareholders,

This letter is to serve as my first corporate communication to those shareholders who have shown interest in Metiscan, Inc. ("Metiscan" or "the Company"), a Delaware corporation.

As many of you already know on June 30th, 2011 Metiscan went through a metamorphosis. Metiscan divested all of its operating subsidiaries, replaced its management team and acquired Aclor, Inc. and its wholly owned subsidiary Aclor Servicios Administrativos, S. de R.L. This event marked Metiscan's entry into the consumer and office paper converter industry with its new seasoned management team ready to execute their vision of expanding Aclor's current operations organically and through acquisition both domestically and internationally. Additionally, our vision includes building a financially strong and fully reporting public company within a respected public marketplace.

Since the change in control, we have begun executing our plan to realize our vision however, as we all know and understand, this will take sometime. With that said, I am writing this letter to outline our goals and expectations for 2012 and provide brief summary of the steps we have taken to build an international brand and showcase our company in a respected public marketplace.

The topics discussed in this letter include:

- 1. Overview of Metiscan and its subsidiary.
- 2. Name change to Aclor International, Inc. and 1:2000 Common Stock Reverse Split;
- 3. Capital Structure Review: Example Pre & Post-Split.
- 4. Form 10-12G and OTCBB;
- 5. Financial Overview: and
- 6. Goals and Expectations for 2012.

1. Overview of Metiscan and its subsidiary.

Metiscan Overview

Metiscan is a holding company focused on growing its organization organically through sales and through acquisitions within the consumer and office paper converter industry supporting private label products for mass retailers. As of the date of this letter, Metiscan has one operating subsidiary Aclor, Inc, which in turn, has one wholly owned Aclor Servicios Administrativos, S. de R.L which operates in Mexico. Metiscan is currently publicly traded on the Pink Sheets (MTIZ.PK).

Aclor, Inc. (our subsidiary):

Founded November 2, 2007, Aclor, Inc. ("Aclor") is a Laredo, Texas based Company that manufactures and sells private label three ring binders and paper to support the consumer and office supplies market primarily in the United States. Aclor has offices in Laredo, Texas, and Monterrey, Nuevo Leon, Mexico, as well as a manufacturing facility leased by Aclor's wholly owned subsidiary, Aclor Servicios Administrativos, S. de R.L., in Nuevo Laredo, Tamaulipas, Mexico. Aclor's headquarter office is located in

11204 Mcpherson Road, Suite#116, Laredo, TX 78041. We are a leader within the consumer and office paper converter industry.

2. Name change to Aclor International, Inc. and 1:2000 Common Stock Reverse Split

On October 31st, 2011, the Company's Board of Directors and majority shareholders approved the change of Metiscan's name and approved a 1 for 2,000 reverse split of our issued and outstanding common stock, which name change was further amended on November 3rd, 2011 to **Aclor International**, **Inc.** Metiscan's subsidiary, Aclor, Inc. (Aclor) is a supplier of goods to major retailers and numerous small to midsized businesses in the Americas, Asia Pacific and Europe. Changing the name of Metiscan, Inc. to Aclor International, Inc. allows our Company to establish itself as an international brand with its customers as well as within the public marketplace.

Our SEC counsel filed a certificate of amendment with the Delaware Secretary of State on November 3, 2011 for the said name change and reverse stock split. The Company also obtained a new CUSIP number that reflects both our name change and reverse split. We originally believed the name change and reverse stock split would be effective on December 5, 2011, however, given that both are subject to FINRA's approval we have updated our expectation that approval may occur before the end of this calendar year.

Upon the effectiveness of the reverse stock split, all earnings per common share amounts, references to common stock and stockholders' equity amounts will be restated as if the reverse stock split had occurred as of the earliest period presented. The reverse split will affect our issued and outstanding common stock and the number of shares of common stock underlying our issued and outstanding convertible preferred stock, including Series D and Series H preferred stock. The conversion rate of Series D and Series H preferred stock will be reduced by 2000 times. The issued and outstanding number of shares and par value of these preferred stock will not be affected.

3. Capital Structure Review: Example Pre & Post-Split.

Our authorized capital stock consists of 10,010,000,000 shares, of which 10,000,000,000 shares are common stock, par value of \$.0001 per share, and 10,000,000 shares are preferred stock, par value of \$.0001 per share.

As of November 30, 2011, the following shares of preferred stock and common stock are issued and outstanding: 500,000 shares of Series D Preferred Stock, 45 shares of Series E Preferred Stock (another 6 shares have been redeemed but not cancelled yet as of November 30, 2011), 57 shares of Series F Preferred Stock (another 6 shares have been redeemed but not cancelled yet as of November 30, 2011), 1,078,460 shares of Series G Preferred Stock and 2,578,460 shares of Series H Preferred Stock, 6,832,150,554 shares of common stock.

For more information regarding the description of securities please review Item 11. in our <u>Form 10</u> filed with the SEC on Dec 1, 2011.

Our SEC counsel filed a certificate of amendment with the Delaware Secretary of State on November 3, 2011 to effectuate a 1:2000 reverse stock split.

THE FOLLOWING IS FOR EXAMPLE PURPOSES ONLY AND IS REPRESENTED AS IF THE REVERSE STOCK SPLIT TOOK PLACE ON NOVEMBER 30TH, 2011.

Security Class	Pre-Split	Post Split
Common	6,832,150,554	3,416,075
Preferred C	Cancelled June 30 th , 2011	None
Preferred D	500,000	500,000
Preferred E	45	45
Preferred F	57	57
Preferred G	1,078,460	1,078,460
Preferred H	2,578,460	2,578,460
Closing Bid	\$0.0006	\$1.20

UPON THE EFFECTIVENESS OF THE REVERSE STOCK SPLIT, ALL EARNINGS PER COMMON SHARE AMOUNTS, REFERENCES TO COMMON STOCK AND STOCKHOLDERS' EQUITY AMOUNTS WILL BE RESTATED AS IF THE REVERSE STOCK SPLIT HAD OCCURRED AS OF THE EARLIEST PERIOD PRESENTED. ALL FRACTIONAL SHARES WILL BE ROUNDED UP TO THE NEAREST WHOLE SHARE.

4. Form 10-12G and OTCBB

On Dec 1st, 2011 we filed our Registration Statement on Form 10 with the Securities and Exchange Commission (SEC) such that we may become a fully reporting company. The new registration statement provides more detailed and in-depth information about the Company and its subsidiaries. The name change, reverse split and filing of the new registration statement are all initiatives being taken by the Company's management to make the Company's stock quoted on the Over-the-Counter Bulletin Board (OTCBB). Approval is dependent on SEC. We are currently waiting on comments from the SEC. Once all comments are cleared and the SEC approves our Form 10 we will be a fully reporting issuer and then will have the ability to move our securities to the OTCBB public marketplace.

A copy of our Form 10 and its exhibits can located here. A detailed list of exhibits are listed below.

Exhibit 99.1	Audited Consolidated Financial Statements for year ended December 31, 2010 and 2009	
Exhibit 99.2	Unaudited Consolidated Financial Statements for the three and nine months ended September 30, 2011 and 2010	
Exhibit 99.3	2.3 Unaudited pro forma condensed consolidated financial statements as of and for the three and nine months ended September 2011 and 2010 and and for the year ended December 31, 2010 and 2009	
(b) I	Exhibits	
Exhibit No.	Description	
3(i)	Articles of Incorporation**	
3(ii)	Bylaws**	
10.1	Acquisition Agreement with Aclor, Inc.	
10.2	Share Exchange Agreement with Mr. Zuoru He	
10.3	Debt Conversion Agreement with Go Right Holding Limited	
10.4	Debt Conversion Agreement with Ever Thrive Limited	
10.5	Debt Conversion Agreement with Mr. Forth Wu.	
10.6	Debt Conversion Agreement with Mr. Zuoru He	
21	Subsidiaries of the Registrant	
23.1	Consent of Auditor	
99.1	Audited Consolidated Financial Statements for year ended December 31, 2010 and 2009	
99.2	Unaudited Consolidated Financial Statements for the nine months ended September 30, 2011 and 2010	
99.3	Unaudited pro forma condensed consolidated financial statements as of and for the nine months ended September 30, 2011 and	
	2010 and and for the year ended December 31, 2010 and 2009	

5. Financial Overview

Below is a financial overview of Metiscan. More detailed information can be located here.

During the nine months ended September 30th, 2011, compared to the same period last year, revenues were down 3.3%, however the Company yielded positive gross profits up by 149%, reduced its expenses by 31%, increased other income by 123%, and yielded a positive net income of \$730,339.

Statement of Income (US \$)	9 Months Ended Sept 30, 2011	9 Months Ended Sept 30, 2010
Revenues	12,147,540	12,564,606
Gross Profit	862,097	(1,760,235)
Total Expenses	1,449,903	2,098,045
Income (Loss) from Operations	(587,806)	(3,858,280)
Other Income (Expenses)	1,318,145	590,048
Net Income (Loss)	730,339	(3,268,232)

Furthermore, during the 9 months ended September 30, 2011, compared to the year-end balance sheet of 2010, total assets were down by -4.6%, however total liabilities decreased by -56% or \$7,501,572 and shareholders equity increased by 87% or \$6,550,272.

Balance Sheet Data (US\$)	9 Months Ended Sept 30, 2011	12 Months Ended Dec 31st, 2010
Total Assets	19,947,497	20,898,797
Total Liabilities	5,887,051	13,388,623
Stockholders' equity (deficit)	14,060,446	7,510,174

THE FOLLOWING IS FOR EXAMPLE PURPOSES ONLY AND IS REPRESENTED AS IF THE REVERSE STOCK SPLIT TOOK PLACE ON NOVEMBER $30^{\rm TH}$, 2011 IN RELATION TO THE FINANCIALS FOR THE 9 MONTHS ENDED SEPTEMBER $30^{\rm TH}$, 2011.

	Pre-Split	Post-Split
Common Shares	6,832,150,554	3,416,075
Revenue Per Share	\$0.0018	\$3.60
Net Asset Value Per Share	\$0.0021	\$4.11
Closing Bid (Nov 30 th , 2011)	\$0.0060	\$1.20

IN THE EXAMPLE ABOVE, OUR CLOSING BID AS OF NOV 30^{TH} , 2011 WAS BELOW OUR REVENUE PER SHARE AND OUR NET ASSET PER SHARE.

6. Goals and Expectations for 2012

We are looking forward to our future plans as we head into 2012. Some of our goals include the following:

- Approval of our Name Change and Reverse Split by FINRA.
- Approval of our Registration Statement on Form 10 by the SEC.
- Uplisting to the OTCBB public marketplace.
- Organic Growth in new customer retention domestically and internationally.
- Growth through acquisition of like manufacturers.
- Exploration of new business opportunities and markets.

Please be sure to visit our website at www.aclor.com.

For more information about our Company please contact Dylan Yarter of Stock Orange at 214.872.6570.

To a successful 2012!

Sincerely,

Curtis Gung

President and CEO Metiscan, Inc. 11204 Mcpherson Road, Suite#116 Laredo, TX 78041

Safe Harbor Statement: Certain of the statements made in this press release constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause Metiscan's actual results to be materially different from the historical results or from any future results expressed or implied by such forward-looking statements. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "intends," "anticipates" or "plans" to be uncertain and forward-looking. The Company does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law.